VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$28.92+1.04 (+3.73%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
78M of 72M shares
Institutional holders
219
30 new, 37 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
1 buys · 33 sales
Net sold $12.07M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Behzad Aghazadeh | 5,610,000 | 8.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 5,340,522 | 7.40% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick G. Enright | 5,184,062 | 8.40% | 13D (active) amendment | Oct 31, 2024 |
| T. Rowe Price Associates, Inc. | 4,573,684 | 6.40% | 13G (passive) amendment | Mar 31, 2026 |
| State Street Corporation | 4,148,786 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Deep Track Capital, LP | 3,921,362 | 5.50% | 13G (passive) | Mar 4, 2026 |
| Yue Tang | 3,426,887 | 5.37% | 13G (passive) | Jun 30, 2025 |
| Deerfield Partners, L.P. | 3,348,117 | 5.25% | 13G (passive) | Jun 6, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VERA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,747,760 | 7.98% | $246.64M | +659,658 | 0.00% |
| Avoro Capital Advisors LLC | 5,723,888 | 7.94% | $245.61M | −165,000 | 2.21% |
| State Street Corp | 4,148,786 | 5.76% | $178.02M | +785,148 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 4,012,936 | 5.57% | $172.20K | −561,094 | 0.02% |
| Deep Track Capital, LP | 4,000,000 | 5.55% | $171.64M | −106,067 | 2.50% |
| Deerfield Management Company, L.P. (Series C) | 3,916,400 | 5.43% | $168.05M | +194,300 | 1.75% |
| Kynam Capital Management, LP | 2,890,059 | 4.01% | $124.01M | −508,165 | 6.85% |
| Morgan Stanley | 2,799,459 | 3.88% | $120.12M | +2,430,699 | 0.01% |
| Sofinnova Investments, Inc. | 2,793,987 | 3.88% | $119.89M | – | 6.20% |
| FMR LLC | 2,774,070 | 3.85% | $119.04M | +97,648 | 0.01% |
| Vanguard Capital Management LLC | 2,755,413 | 3.82% | $118.23M | +71,806 | 0.00% |
| Eversept Partners, LP | 2,212,770 | 3.07% | $94.95M | +39,484 | 4.93% |
| Logos Global Management LP | 2,200,000 | 3.05% | $94.40M | New | 4.06% |
| Integral Health Asset Management, LLC | 1,750,000 | 2.43% | $75.09M | +150,000 | 2.97% |
| Bellevue Group AG | 1,710,808 | 2.37% | $73.41M | +37 | 1.54% |
| Geode Capital Management, LLC | 1,692,442 | 2.35% | $72.64M | +122,365 | 0.00% |
| Alliancebernstein L.P. | 1,591,043 | 2.21% | $64.01M | +276,801 | 0.02% |
| Goldman Sachs Group Inc | 1,380,835 | 1.92% | $59.25M | +246,866 | 0.01% |
| Frontier Capital Management Co LLC | 1,295,405 | 1.80% | $55.59M | +743,912 | 0.52% |
| Pictet Asset Management Holding SA | 1,249,414 | 1.73% | $53.63M | +197,831 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 219 | 78M | 100.0% | 30 / 100 | 66 / 37 | 13M | 8M |
| Q1 2026 | 229 | 72M | 100.0% | 47 / 94 | 65 / 29 | 11M | 10M |
| Q4 2025 | 214 | 74M | 100.0% | 62 / 79 | 59 / 18 | 18M | 9M |
| Q3 2025 | 175 | 65M | 90.4% | 35 / 66 | 49 / 32 | 12M | 11M |
| Q2 2025 | 172 | 64M | 88.7% | 34 / 71 | 48 / 40 | 15M | 15M |
| Q1 2025 | 179 | 64M | 88.3% | 34 / 73 | 46 / 32 | 10M | 9M |
| Q4 2024 | 178 | 63M | 87.3% | 32 / 97 | 36 / 23 | 13M | 4M |
| Q3 2024 | 173 | 54M | 74.4% | 27 / 67 | 53 / 24 | 10M | 7M |
| Q2 2024 | 171 | 55M | 75.8% | 38 / 68 | 54 / 23 | 10M | 10M |
| Q1 2024 | 159 | 55M | 76.2% | 72 / 52 | 31 / 8 | 24M | 11M |
| Q4 2023 | 95 | 43M | 59.5% | 22 / 33 | 21 / 10 | 8M | 4M |
| Q3 2023 | 84 | 39M | 54.5% | 17 / 38 | 15 / 8 | 6M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VERA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,650,187 | 3.68% | $113.72M | 1.06% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,933,728 | 2.68% | $82.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,664,738 | 2.31% | $71.43M | 0.09% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,014,457 | 1.41% | $43.53M | 0.30% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 872,624 | 1.21% | $31.00M | 0.03% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 784,306 | 1.09% | $33.65M | 0.28% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 759,558 | 1.05% | $32.59M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 698,793 | 0.97% | $22.43M | 0.07% | Jul 31, 2026 |
| Small Cap Growth Fund | 658,959 | 0.91% | $21.15M | 0.38% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 647,781 | 0.90% | $27.80M | 0.28% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 590,030 | 0.82% | $25.32M | 0.16% | Jun 30, 2026 |
| iShares Biotechnology ETF | 414,491 | 0.58% | $17.79M | 0.20% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 376,729 | 0.52% | $16.17M | 0.52% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 333,353 | 0.46% | $11.84M | 0.03% | May 31, 2026 |
| Ab Discovery Growth Fund, Inc. | 323,006 | 0.45% | $13.86M | 0.48% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marshall Fordyce | PRESIDENT AND CEO, Director | 475,774 | 0.66% | Sep 17, 2026 |
| Joseph R. Young | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 | 0.11% | Sep 14, 2026 |
| Nancy Lee Boman | Chief Regulatory Officer | 44,987 | 0.06% | Aug 5, 2026 |
| Jane Wright-Mitchell | Chief Legal Officer | 42,403 | 0.06% | Mar 25, 2026 |
| Laurence Matthew Skelton | Chief Commercial Officer | 64,218 | 0.09% | Feb 25, 2026 |
| Sean Grant | CHIEF FINANCIAL OFFICER | 119,181 | 0.17% | Feb 25, 2026 |
| David Lee Johnson | Chief Operating Officer | 45,727 | 0.06% | Feb 25, 2026 |
| William D. Turner | Chief Regulatory Officer | 45,313 | 0.06% | Feb 25, 2026 |
| Robert Brenner | Chief Medical Officer | 50,947 | 0.07% | Feb 25, 2026 |
| Jason S. Carter | Chief Legal Officer | 49,136 | 0.07% | Nov 25, 2025 |
| Scott W. Morrison | Director | – | – | May 26, 2026 |
| Michael Morrissey | Director | 0 | – | May 26, 2026 |
| Andrew Cheng | Director | 17,488 | 0.02% | May 26, 2026 |
| James R. Meyers | Director | – | – | May 26, 2026 |
| Kimball Hall | Director | 0 | – | May 26, 2026 |
| Christy J. Oliger | Director | 2,987 | 0.00% | May 26, 2026 |
| Beth C. Seidenberg | Director | 135,565 | 0.19% | May 26, 2026 |
| Patrick G. Enright | Director | 3,602,475 | 5.00% | May 26, 2026 |
| Christopher Hite | Director | – | – | Mar 9, 2026 |
| Maha Katabi | Director | 5,975,429 | 8.29% | May 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 15, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −18,500 | $37.00 | $684.50K | 235,244 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Sep 11, 2026 | Option exercise | +5,000 | $3.94 | $19.70K | 80,754 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 2, 2026 | Sale(10b5-1 plan) | −18,500 | $35.12 | $649.72K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 2, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Nancy Lee Boman Chief Regulatory Officer | Aug 3, 2026 | Award | +44,987 | – | – | 44,987 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −32,550 | $42.07 | $1.37M | 247,944 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −10,500 | $42.86 | $450.03K | 237,444 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −2,200 | $43.59 | $95.90K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −1,000 | $40.78 | $40.78K | 280,494 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Option exercise | +46,250 | $2.90 | $134.13K | 281,494 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −10,500 | $42.86 | $450.03K | 154,194 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −1,000 | $40.78 | $40.78K | 197,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −32,550 | $42.07 | $1.37M | 164,694 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −2,200 | $43.59 | $95.90K | 151,994 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −18,412 | $37.93 | $698.37K | 235,332 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −88 | $38.43 | $3.38K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −88 | $38.43 | $3.38K | 198,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −18,412 | $37.93 | $698.37K | 198,332 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −14,219 | $36.64 | $520.98K | 239,525 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −4,281 | $37.09 | $158.78K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −4,281 | $37.09 | $158.78K | 216,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −14,219 | $36.64 | $520.98K | 221,025 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −7,921 | $44.58 | $353.12K | 236,144 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −900 | $45.51 | $40.96K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −14,130 | $43.66 | $616.92K | 244,065 |
| Jane Wright-Mitchell Chief Legal Officer | Mar 23, 2026 | Award | +42,403 | – | – | 42,403 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Mar 13, 2026 | Option exercise | +10,000 | $3.94 | $39.40K | 75,754 |
| William D. Turner Chief Regulatory Officer | Feb 23, 2026 | Sale | −2,187 | $41.98 | $91.81K | 45,313 |
| Sean Grant CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sale | −4,949 | $41.98 | $207.76K | 114,181 |
| Robert Brenner Chief Medical Officer | Feb 23, 2026 | Sale | −2,151 | $41.98 | $90.30K | 50,947 |
| Laurence Matthew Skelton Chief Commercial Officer | Feb 23, 2026 | Sale | −1,582 | $41.98 | $66.41K | 64,218 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 23, 2026 | Sale | −16,925 | $41.98 | $710.51K | 257,163 |
| David Lee Johnson Chief Operating Officer | Feb 23, 2026 | Sale | −2,579 | $41.98 | $108.27K | 45,727 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Feb 23, 2026 | Sale | −3,117 | $41.98 | $130.85K | 64,722 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Feb 4, 2026 | Award | +10,000 | – | – | 67,839 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 4, 2026 | Award | +68,800 | – | – | 274,088 |
| Sean Grant CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Award | +25,000 | – | – | 119,130 |
| Robert Brenner Chief Medical Officer | Feb 4, 2026 | Award | +25,000 | – | – | 53,098 |
| Laurence Matthew Skelton Chief Commercial Officer | Feb 4, 2026 | Award | +20,000 | – | – | 65,800 |
| William D. Turner Chief Regulatory Officer | Feb 4, 2026 | Award | +25,000 | – | – | 47,500 |
| David Lee Johnson Chief Operating Officer | Feb 4, 2026 | Award | +20,000 | – | – | 48,306 |
| William D. Turner Chief Regulatory Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −10,000 | $50.08 | $500.80K | 22,500 |
| William D. Turner Chief Regulatory Officer | Dec 15, 2025 | Option exercise | +10,000 | $15.53 | $155.30K | 32,500 |
| Patrick G. Enright Director | Dec 11, 2025 | Buy | +5,882 | $42.50 | $249.99K | 5,882 |
| William D. Turner Chief Regulatory Officer | Dec 8, 2025 | Option exercise | +10,000 | $15.53 | $155.30K | 32,500 |
| William D. Turner Chief Regulatory Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −10,000 | $45.31 | $453.10K | 22,500 |
| William D. Turner Chief Regulatory Officer | Dec 3, 2025 | Option exercise | +10,000 | $15.53 | $155.30K | 32,500 |
| William D. Turner Chief Regulatory Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −10,000 | $40.00 | $400.00K | 22,500 |
| Jason S. Carter Chief Legal Officer | Nov 21, 2025 | Sale | −3,864 | $27.82 | $107.50K | 49,136 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Nov 13, 2025 | Option exercise | +10,000 | $3.94 | $39.40K | 57,839 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Nov 11, 2025 | Sale | −15,000 | $29.06 | $435.90K | 47,839 |
| Patrick G. Enright Director | Jun 24, 2025 | Buy | +13,536 | $22.35 | $302.53K | 1,797,619 |
| Patrick G. Enright Director | Jun 24, 2025 | Buy | +27,071 | $22.35 | $605.04K | 3,596,593 |
| Patrick G. Enright Director | Jun 23, 2025 | Buy | +139,595 | $20.87 | $2.91M | 3,569,522 |
| Patrick G. Enright Director | Jun 23, 2025 | Buy | +69,798 | $20.87 | $1.46M | 1,784,083 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 26, 2025 | Sale(10b5-1 plan) | −1,100 | $28.32 | $31.15K | 204,665 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 26, 2025 | Sale(10b5-1 plan) | −7,975 | $27.55 | $219.71K | 205,765 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Fordyce Marshall Director, Officer | Sep 2, 2026 | 64,750 | $2.22M | Sep 2, 2026 | Exercise of Stock Options |
| Fordyce Marshall Director, Officer | Jun 23, 2026 | 74,000 | $2.84M | Jun 23, 2026 | Exercise of Stock Options |
| Fordyce Marshall Director, Officer | May 12, 2026 | 18,500 | $677.29K | May 12, 2026 | Exercise of Stock Options |
| Fordyce Marshall Director, Officer | Apr 14, 2026 | 22,951 | $1.00M | Apr 14, 2026 | Restricted Stock Units |
| Fordyce Marshall Officer | Feb 23, 2026 | 16,600 | $697.78K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| L. Johnson David Officer | Feb 23, 2026 | 2,900 | $121.90K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Brenner Robert Officer | Feb 23, 2026 | 2,500 | $105.09K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Grant Sean Officer | Feb 23, 2026 | 5,700 | $239.60K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Donald Turner William Officer | Feb 23, 2026 | 2,600 | $109.29K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Skelton Laurence Officer | Feb 23, 2026 | 1,800 | $75.66K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Turner William Officer | Dec 15, 2025 | 10,000 | $498.00K | Dec 15, 2025 | Exercise of Stock Options |
| Turner William Officer | Dec 8, 2025 | 10,000 | $449.00K | Dec 8, 2025 | Exercise of Stock Options |
| Turner William Officer | Dec 3, 2025 | 10,000 | $372.50K | Dec 3, 2025 | Exercise of Stock Options |
| Jason S. Carter Officer | Nov 24, 2025 | 3,864 | $107.69K | Nov 21, 2025 | Restricted Stock Unit Award |
| Fordyce Marshall Director, Officer | Feb 26, 2025 | 9,075 | $245.93K | Feb 26, 2025 | Restricted Stock Units |